Applicants: Graham P. Allaway, et al.

Serial No.: 09/460,216 Filed: December 13, 1999

Page 3

or substitute computer readable form (CRF) copy of the "sequence listing"; and an initial or substitute paper copy of the "sequence listing," as well as an amendment directing its entry into the specification.

In response, applicants contend that the February 24, 2000 Notice to Comply was issued in error. Applicants contend that a paper copy and computer readable copy of the sequence listing were provided to the United States Patent and Trademark Office on December 13, 1999. A copy of the return postcard stamped by the U.S. Patent and Trademark Office acknowledging receipt of these items is attached hereto as **Exhibit B**.

In addition, in a April 13, 2000 telephone conference between Anthony Love of the Initial Patent Examination Division of the United States Patent and Trademark Office and Mr. Spencer Schneider of the undersigned attorney's office, Mr. Love stated that both the paper copy and computer readable copy of the sequence listing were received and that the February 24, 2000 Notice to Comply was issued in error. In addition, Mr. Love stated that a Notice of Withdrawal of the February 24, 2000 Notice to Comply would be issued.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants: Graham P. Allaway, et al.

Serial No.: 09/460,216 Filed: December 13, 1999

Page 4

No fee, is deemed necessary in connection with the filing of this However, if any fee is required, authorization Communication. is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

No. 28,678

White

Registration No. 28,678 Attorney for Applicants Cooper & Dunham, LLP

1185 Avenue of the Americas New York, New York 10036

(212) 278-0400



Applicant	Graham P. Allaway,	et al.		•	
Client	Progenics (2048)	File No	50875-F-PCT-U&tty.	JPW/SHS	
Date	December 13, 1999		jc511 U	U.S. PTO	
	Kindly acknowle	edge receipt of t	jc511 U.S. PTO 09/460216		

New Patent Application in connection with Graham P. Allaway, et al., U.S. Serial Not Yet Known, filed December 13, 1999 for METHODS FOR PREVENTION HIV-1 INFECTION OF CD4+ CELLS including Title Page, Specification (pgs.1-58), Claims (pgs.59-68), Abstract (pg.69)Formal Drawings (10 sheets), 1 loose set of formal drawings, Transmittal Letter in Triplicate, a Preliminary Amendment, Declaration and Powerfor Authorney (unsigned), computer diskette containing CRF, Statement in Accordance with COPCING 1999, a check in the amount of \$380.00, and Express Mail Certificate of Mailing bearing Label No. BL 278 887 487 US, dated December 13, 1999.

DATE DUE: December 13, 1999 date stamp hereon and returning to us.

DOCKET CLERK





UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARK Washington, D.C. 20231

APPLICATION NUMBER FILING/RECEIPT DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NO./TITLE

09/460,216

12/13/99

ALLAWAY

G

50875-F-PCT-

0242/0224

COOPER & DUNHAM LLE 1185 AVENUE OF THE AMERICAS NEW YORK NY 10036

1633

DATE MAILED:

02/24/00

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS 08/24/3000 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

An Application Number and Filing Date have been assigned to this application. The items indicated below, however, are missing. Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file a sequence listing in compliance with 37 CFR 1.821 - 1.825 to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- This application fails to comply with the requirements of 37 CFR 1.821 1.825.
 This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
 A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 The computer readable form that has been filled with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
 The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:

☐ 7. OTHER:___

<u>U</u>	An initial or	r substitute computer	readable form	(CRF) copy	y of the "Se	equence Listing."
----------	---------------	-----------------------	---------------	------------	--------------	-------------------

- An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

- ☐ For Rules Interpretation, call (703) 308-1123.
- ☐ For CRF submission help, call (703) 308-4212.
- For Patentin software help, call (703) 308-6856.

Customer Service Cent r

Initial Patent Examination Division (703) 308-1202

